Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

NCT00725764 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00725764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00725764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the MET RTK Inhibitor GSK1363089 (Formerly XL880) in Subjects With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
August 27, 2007
Completion date
May 2, 2009
Enrollment
14 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, head and neck